{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["7(8)"],"submitter":["Buglioni S"],"pubmed_abstract":["Whether PD-L1 expression is associated with survival outcomes in gastric cancer (GC) is controversial. The inhibition of the PD-1/PD-L1 pathway is effective against genomically unstable tumors. Hypothesizing that also the clinical significance of PD-L1 might be dependent on the activation of molecular circuits ensuring genomic stability, we evaluated PD-L1 expression in tissue samples from 72 advanced GC patients treated with first-line chemotherapy. Samples were already characterized for DNA damage repair (DDR) component expression (pATM, pChk1, pWee1, γ-H2AX and pRPA2) along with mutations in DDR-linked genes (<i>TP53</i> and <i>ARID1A</i>). Overall, PD-L1 expression was not associated with progression-free survival (PFS) and overall survival (OS), independently on whether we considered "],"journal":["Oncoimmunology"],"pagination":["e1457602"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6136851"],"repository":["biostudies-literature"],"pubmed_title":["The clinical significance of PD-L1 in advanced gastric cancer is dependent on <i>ARID1A</i> mutations and ATM expression."],"pmcid":["PMC6136851"],"pubmed_authors":["Buglioni S","Diodoro MG","Ciliberto G","Fanciulli M","Barba M","Pescarmona E","Sperati F","Maugeri-Sacca M","Goeman F","Vitale I","De Maria R","De Nicola F","Terrenato I","Pizzuti L","Di Lauro L","Casini B","Sergi D","Melucci E","Amoreo CA","Pallocca M","Mazzotta M","Gallo E","Vici P"],"additional_accession":[]},"is_claimable":false,"name":"The clinical significance of PD-L1 in advanced gastric cancer is dependent on <i>ARID1A</i> mutations and ATM expression.","description":"Whether PD-L1 expression is associated with survival outcomes in gastric cancer (GC) is controversial. The inhibition of the PD-1/PD-L1 pathway is effective against genomically unstable tumors. Hypothesizing that also the clinical significance of PD-L1 might be dependent on the activation of molecular circuits ensuring genomic stability, we evaluated PD-L1 expression in tissue samples from 72 advanced GC patients treated with first-line chemotherapy. Samples were already characterized for DNA damage repair (DDR) component expression (pATM, pChk1, pWee1, γ-H2AX and pRPA2) along with mutations in DDR-linked genes (<i>TP53</i> and <i>ARID1A</i>). Overall, PD-L1 expression was not associated with progression-free survival (PFS) and overall survival (OS), independently on whether we considered ","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018","modification":"2025-04-04T10:18:42.366Z","creation":"2019-06-06T22:45:52Z"},"accession":"S-EPMC6136851","cross_references":{"pubmed":["30221053"],"doi":["10.1080/2162402x.2018.1457602","10.1080/2162402X.2018.1457602"]}}